Effect of the Common -866G/A Polymorphism of the Uncoupling Protein 2 Gene on Weight Loss and Body Composition under Sibutramine Therapy in an Obese Taiwanese Population

Hsiao, Tun Jen; Wu, Lawrence Shih Hsin; Hwang, Yuchi; Huang, Shih Yi; Lin, Eugene

doi:10.1007/bf03256359

Cited by 15 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, our findings support the hypothesis that ADIPOQ rs266729 may help predict weight reduction and fat loss in response to sibutramine therapy together with other markers found in some previous studies 3–7. Independent replications are needed to confirm the role of the ADIPOQ rs266729 polymorphism found in this study.…”

Section: Resultssupporting

confidence: 90%

“…Our previous findings6,7 mainly reported of the association studies of sibutramine with the GNB3 rs5443 and UCP2 rs659366 polymorphisms. In this work, we extended the previous research to test the hypothesis that ADIPOQ rs266729 may influence weight loss and fat change in response to sibutramine treatment amongst Taiwanese obese individuals.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity

Hsiao

Huang

et al. 2010

CPAA

Self Cite

View full text Add to dashboard Cite

In this study, we aimed to explore whether a common single nucleotide polymorphism (SNP), rs266729 (−11,377C > G), in the adiponectin C1Q and collagen domain containing (ADIPOQ) gene could influence weight reduction and fat change under sibutramine therapy in an obese population. There were 131 obese Taiwanese patients, including 44 in the placebo group and 87 in the sibutramine (10 mg daily) group. We assessed the measures of weight loss and body fat reduction at the end of the 12-week treatment period by analysis of covariance (ANCOVA) models using gender, baseline weight, and baseline percent body fat as covariates. By comparing the placebo and sibutramine groups with ANCOVA, our data revealed a strong effect of sibutramine on percent body fat loss (1.9 ± 0.3 vs 4.6 ± 0.5%; P < 0.001) and on weight reduction (2.8 ± 2.0 vs 7.9 ± 1.6 kg; P < 0.001) for subjects with the CC genotype. On the contrary, sibutramine had no significant effect on percent body fat loss or on weight loss in the GG and GC individuals. The results suggest that the SNP rs266729 of the ADIPOQ gene may contribute to weight reduction and fat loss in response to sibutramine therapy in Taiwanese obese patients.

show abstract

Section: Resultssupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity

Hsiao

Huang

et al. 2010

CPAA

Self Cite

View full text Add to dashboard Cite

show abstract

“…Two other studies reported that in obese children with the A/A genotype the resting energy expenditure was increased [47], and in Pima Indians the SNP was associated with increased 24-hour energy expenditure [48]. A recent study reported a strong effect of sibutramine on weight and body fat percentage loss in the combined UCP2 A/A + G/A of the SNP G(−866)A in a Taiwanese population [49]. Interesting to note that in their placebo group, the A/A genotype showed the least weight and fat percentage loss, which was in agreement with a study conducted in Korean women [46], indicating that the effect of the UCP2 G(−866)A polymorphism might be universal, at least for Asian.…”

Section: Discussionmentioning

confidence: 99%

Uncoupling protein 2 gene polymorphisms are associated with obesity

Oktavianthi

Trimarsanto

Febinia

et al. 2012

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundUncoupling protein 2 (UCP2) gene polymorphisms have been reported as genetic risk factors for obesity and type 2 diabetes mellitus (T2DM). We examined the association of commonly observed UCP2 G(−866)A (rs659366) and Ala55Val (C > T) (rs660339) single nucleotide polymorphisms (SNPs) with obesity, high fasting plasma glucose, and serum lipids in a Balinese population.MethodsA total of 603 participants (278 urban and 325 rural subjects) were recruited from Bali Island, Indonesia. Fasting plasma glucose (FPG), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) were measured. Obesity was determined based on WHO classifications for adult Asians. Participants were genotyped for G(−866)A and Ala55Val polymorphisms of the UCP2 gene.ResultsObesity prevalence was higher in urban subjects (51%) as compared to rural subjects (23%). The genotype, minor allele (MAF), and heterozygosity frequencies were similar between urban and rural subjects for both SNPs. All genotype frequencies were in Hardy-Weinberg equilibrium. A combined analysis of genotypes and environment revealed that the urban subjects carrying the A/A genotype of the G(−866)A SNP have higher BMI than the rural subjects with the same genotype. Since the two SNPs showed strong linkage disequilibrium (D’ = 0.946, r2 = 0.657), a haplotype analysis was performed. We found that the AT haplotype was associated with high BMI only when the urban environment was taken into account.ConclusionsWe have demonstrated the importance of environmental settings in studying the influence of the common UCP2 gene polymorphisms in the development of obesity in a Balinese population.

show abstract

“…Very recently, Hsiao et al57 used the same patients in which they had investigated the role of GNβ3 polymorphism54 to study the role of −866G/A polymorphism on weight loss in patients treated with sibutramine. The uncoupling protein 2 (UCP2) gene encodes a mitochondrial transporter protein, which is highly expressed in adipose tissue, skeletal muscle, and pancreatic islets 58.…”

Section: Predictors Associated With Sibutramine Treatmentsmentioning

confidence: 99%

Predictors of weight loss and maintenance in patients treated with antiobesity drugs

Guaraldi¹,

Pagotto²,

Pasquali³

2011

DMSO

View full text Add to dashboard Cite

Background:The prevalence of obesity and related diseases has increased enormously in the last few decades, becoming a very important medical and social issue. Because of the increasing number of people who need weight loss therapies and the high costs associated with these, the search for reliable predictors of success for weight loss and weight maintenance treatments has become a priority.Objective:A literature review was undertaken to identify possible predictors of outcome of weight loss and weight maintenance in patients treated with antiobesity drugs.Results:For the majority of variables, published data are not sufficient to define their role on final outcomes. Among all considered factors, only early response to treatment appeared to be a reliable positive predictor, and diabetes a negative predictor of weight loss and maintenance.Conclusion:To date, no definitive results have been obtained. Due to the great benefits of reliable predictors of outcome associated to currently available antiobesity drugs and those under development, identifying these predictors has to be supported and encouraged.

show abstract

Effect of the Common -866G/A Polymorphism of the Uncoupling Protein 2 Gene on Weight Loss and Body Composition under Sibutramine Therapy in an Obese Taiwanese Population

Cited by 15 publications

References 26 publications

A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity

A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity

Uncoupling protein 2 gene polymorphisms are associated with obesity

Predictors of weight loss and maintenance in patients treated with antiobesity drugs

Contact Info

Product

Resources

About